April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Retinal Vascular Diseases in Saudi Arabia
Author Affiliations & Notes
  • Saeed Talab Alshahrani
    Vitro/Retinal, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • J Fernando Arevalo
    Vitro/Retinal, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
    Retina division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
  • Footnotes
    Commercial Relationships Saeed Alshahrani, None; J Fernando Arevalo, ALCON LABORATORIES (C), IRIDIX (F), KING KHALED EYE SPECIALIST HOSPITAL (S), NOVARTIS PHARMACEUTICALS CORP (F), OPTOS (F), SECOND SIGHT LLC (F), SPRINGER SBM LLC (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1777. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saeed Talab Alshahrani, J Fernando Arevalo; Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Retinal Vascular Diseases in Saudi Arabia. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1777. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To study the efficacy and safety of an intravitreal implant (sustained release of dexamethasone, Ozurdex®) for the treatment of macular edema in retinal vascular diseases in Saudi Arabia

Methods: Retrospective non-consecutive study of patients with macular edema secondary to central retinal vein occlusion, branch retinal vein occlusion and diabetic retinopathy treated with a dexamethasone implant of 0.7 mg. Follow-up visits were performed at 1 month, 3 months and 6 months. Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity, Goldmann tonometry and macular thickness on spectral domain-optical coherence tomography (SD-OCT) were registered.

Results: Fourteen eyes with macular edema of 14 patients were included; 2 with branch retinal vein occlusion, 7 with central retinal vein occlusion, and 5 with diabetic macular edema. Nine (64.2%) eyes improved best-corrected visual acuity (BCVA). Four (28.5%) eyes achieved 3 lines or more of BCVA gain, 5 (35.7%) eyes showed improvement of BCVA of less than 3 lines (1 to 2 lines), and 5 eyes (35.7%) remained stable at 1 month. Central macular thickness (CMT) at base line (BL) had a mean of 637 µm (range: 310 to 950 µm). All cases showed anatomical response at 1 month with a mean CMT of 272 µm (range: 140 to 460 µm). In 9 (64.2%) eyes the macular edema resolved at month 1. Eleven (78.5%) eyes showed recurrence of macular edema at month 3 with a mean CMT of 493 µm (range: 157 to 1430 µm). At 6 months the CMT had a mean of 522 µm (range: 94 to 1083 µm). All these differences were statistically significant when compared to BL (p < 0.05). High intraocular pressure (> 21 mm Hg) was observed after implantation in 5 (35.7%) eyes but it was controlled with topical anti-glaucoma medications. No other serious side effects were observed.

Conclusions: Our study showed the efficacy and safety of an intravitreal dexamethasone implant in the treatment of macular edema due to retinal vascular diseases. Functional and anatomical efficacy was achieved at month 1. However, the effect lasted less than 3 months in most eyes, which is shorter than previously published.

Keywords: 585 macula/fovea • 749 vascular occlusion/vascular occlusive disease • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×